News Home

PartnerRe third-party capital reaches $1bn

The carrier has recently gained sidecar investment by Covea and private equity firm Olympus Partners.

Texas Big Freeze: Why are the numbers so far apart?

As some in the market believe the winter claims will remain notably below $20bn, there are multiple factors creating challenges in assessing the event.

CEA prices $215mn cat bond at bottom of target range

The authority upsized the Ursa Re bond to $215mn, the top end of its target, as pricing fell 11% during marketing.

SiriusPoint launches with over $3bn in capital

The merger of Third Point Re with Sirius goes live.

• Berger to retire as Ascot promotes Thompson to Bermuda CEO
• Universal narrows Q4 loss despite $76mn weather losses
• RSA posts £259mn Covid-19 loss for 2020
• US winter storm losses likely to exceed $10bn: AIR
• Perils cuts February 2020 UK winter flood cost to £368mn
• PartnerRe non-life segment swings to Q4 profit

Opinion

When there is nothing average about cat losses, why benchmark to the mean?

ILS market enjoying spoils of post-Covid interest

Swiss Re's fund launch is a bigger ILS pivot than it may seem

Aon's new cat facility points to ILS ambitions from backers

Analysis

Evolving commutation practices tested by Covid and final Irma tie-up

While uncertainty over Covid may limit early commutations, isolated deals may have been struck, as 2017 contracts in some cases remain open.

Bilateral deals support sidecar growth at 1.1

One estimate suggested around $2bn of new capacity in private deals.

BI aggregation issues will need further testing

Fenchurch Law partner suggests "aggressive" initial claims adjustments will be unwound and the reinsurance context will need specific consideration.

Swiss ILS investment could shrink after recent loss years

Returns have disappointed some institutional investors, but prospective rates may attract fresh investment, sources said.

Supplements

(Re)Connect 2020 - ILS Roundtable

Covid-19 may have been the biggest talking point in the (re)insurance markets this year but arguably, the pandemic is being overtaken by several other factors – ILS market dynamics amongst them.

Investor Guide to ILS: H2 2020

Covid-19 and ILS strategies: locking down diversification benefits.